title: Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.
abstract: Avibactam, a novel β-lactamase inhibitor, has recently been co-formulated with ceftazidime and approved for use in patients with complicated intra-abdominal and urinary tract infections, where no better treatment alternative exists. The basis for its FDA approval has been the extensive clinical experience with ceftazidime and the demonstration in vitro and in animal models that the addition of avibactam reverses resistance to ceftazidime in extended-spectrum β-lactamase and some carbapenemase-producing Enterobacteriaceae. Early clinical data are promising, with efficacy demonstrated in patients with complicated intra-abdominal and urinary tract infections. This review will summarize the in vitro, animal and clinical data available on this agent to date.
authors.affiliation: a Division of Geographic Medicine and Infectious Diseases , Tufts Medical Center and Tufts University School of Medicine , Boston , MA , USA.
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Gardiner
authors.affiliation: a Division of Geographic Medicine and Infectious Diseases , Tufts Medical Center and Tufts University School of Medicine , Boston , MA , USA.
authors.forename: Yoav
authors.initials: Y
authors.lastname: Golan
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D053961:Azabicyclo Compounds / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002442:Ceftazidime / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects; D004755:Enterobacteriaceae / Q000187:drug effects; D006801:Humans; D059413:Intraabdominal Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D004338:Drug Combinations; C000595613:avibactam, ceftazidime drug combination; D002442:Ceftazidime
keywords: Ceftazidime-avibactam; Gram-negative infection; antibiotic resistance; carbapenem-resistant Enterobacteriaceae; β-lactamase; β-lactamase inhibitor